SCHEMBL21601437

SCHEMBL21601437

Cc1ccc(OCCNC(=O)OC(C)(C)C)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.55
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
AAK1 Q2M2I8 2/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
TSHR P16473 2/20 0.45
TTR P02766 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C8 P10632 1/20 0.45
CHRM1 P11229 1/20 0.45
CYP2C9 P11712 1/20 0.45
ADRA1A P35348 1/20 0.45
PPARG P37231 1/20 0.45
HTR2B P41595 1/20 0.45
PPARA Q07869 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SLCO1B3 Q9NPD5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21601440 0.87 AAK1 (0.49) HPGDCA12CA1CA2CA9
SCHEMBL21601445 0.87 SCN9A (0.49) HPGDCA12CA1CA2CA9
SCHEMBL21601453 0.87 KDM4E (0.54) HPGDCA12CA1CA2CA9
SCHEMBL18165160 0.86 CA12 (0.47) CA12CA1CA2CA9AAK1
SCHEMBL28350960 0.86 SSTR4 (0.47) HPGDCA12CA1CA2CA9
SCHEMBL18544342 0.85 CA12 (0.46) HPGDCA12CA1CA2CA9
SCHEMBL18165162 0.85 MGLL (0.53) HPGDCA12CA1CA2CA9
SCHEMBL15869790 0.83 ALDH1A1 (0.55) HPGDCA12CA1CA2CA9
SCHEMBL21595742 0.83 HPGD (0.63) HPGDKDM4EALDH1A1TSHRSMN1; SMN2
SCHEMBL18570014 0.82 ALDH1A1 (0.46) HPGDCA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019244066-A2 PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2019-12-26 WO disclosed